Synovial fluid in antiquity

Sir, We enjoyed Dr Alarcon-Segovia’s paper on the description of synovial fluid and therapeutic arthrocentesis by the Nahuatl Indians of Mexico in pre-Columbian times. We cannot agree, however, with the statement contained therein that Paracelsus is generally considered to be the first to have noted the presence of viscid liquor in the joint cavity. Numerous references to the existence of such fluid in the movable joints are found in the writings of the ancients, beginning with the Hippocratic texts Of the Places of Man and On the Articulations. Galen described the function of synovia as a joint lubricant in his treatise On the Function of the Parts of the Human Body, and in his commentaries on Hippocrates he stresses the importance of examination of the joint fluid: ‘The physicians must examine the nature of the humor which, in a small quantity, envelops the joints, because many swellings of joints do not become purulent due to this humor. This, namely, is a thick humor. . . . Some physicians have already examined these swellings by incising them.’

Much of the early information concerning joint fluid was derived from observations of traumatic injuries, and both Paracelsus and his followers, including Severinus (1542-1602), credit wound surgeons with the origin of the term synovia, which was also known by them as Gliedwasser (joint-water) and Gluttwasser (glow-water).

Gerald P. Rodnan and Thomas G. Benedek
Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA

References

Venous thrombosis in SLE

Sir, The article by Gladman and Urowitz confirmed a susceptibility to venous thrombosis of patients with systemic lupus erythematosus (SLE). Similar observations have been made by Peck, Hoffman, and Franck. Neither of these studies was able to define any specific characteristics which pre-disposed patients to venous thrombosis, although it is noteworthy that 3 of the 17 cases described by the former authors had a circulating anticoagulant. They did not state whether this feature was sought in every instance.

We have recently described 4 patients in whom recurrent or extensive venous thrombosis was associated with the presence of the lupus coagulation inhibitor. This paradox has been previously noted, and in our view is more than a chance association. In our cases further thrombosis was prevented by continuous warfarin treatment over an average period of 6 months. Interestingly, anticoagulation reduced the partial thromboplastin times and made it more difficult to demonstrate the inhibitor. There were no haemorrhagic complications during treatment. We believe that severe venous thrombosis in SLE should suggest the possibility of the lupus circulating anticoagulant, which, if demonstrable, is an indication for long-term anticoagulation.

T. Gibson
Department of Rheumatology, Guy’s Hospital, London SE1

References
Synovial fluid in antiquity.

G P Rodnan and T G Benedek

doi: 10.1136/ard.40.1.103-a

Updated information and services can be found at:
http://ard.bmj.com/content/40/1/103.1.citation

**Email alerting service**

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/